• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm.

作者信息

Kuritzkes Daniel R

机构信息

Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

出版信息

J Infect Dis. 2024 Dec 16;230(6):1297-1298. doi: 10.1093/infdis/jiae214.

DOI:10.1093/infdis/jiae214
PMID:38973073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11646577/
Abstract
摘要

相似文献

1
Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm.莫努匹拉韦与奈玛特韦/利托那韦联用：无需担忧。
J Infect Dis. 2024 Dec 16;230(6):1297-1298. doi: 10.1093/infdis/jiae214.
2
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation.奈玛特韦/利托那韦和莫努匹拉韦对门诊新冠康复者预后的疗效：一项目标试验模拟研究
Emerg Microbes Infect. 2025 Dec;14(1):2469648. doi: 10.1080/22221751.2025.2469648. Epub 2025 Mar 4.
3
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
4
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
5
Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand.泰国门诊患者中使用奈玛特韦/利托那韦、瑞德西韦和莫努匹拉韦治疗新冠病毒病的真实世界有效性和经济分析
J Infect Public Health. 2025 Aug;18(8):102826. doi: 10.1016/j.jiph.2025.102826. Epub 2025 May 13.
6
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.奥密克戎变异株流行期间，未住院的 2 型糖尿病合并 SARS-CoV-2 感染患者接受莫努匹韦或奈玛特韦/利托那韦治疗后的全因住院和死亡分析。
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
7
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.莫努匹韦与奈玛特韦/利托那韦对比治疗早期有症状 COVID-19 患者的抗病毒疗效（PLATCOV）：一项开放标签、2 期、随机、对照、自适应试验。
Lancet Infect Dis. 2024 Jan;24(1):36-45. doi: 10.1016/S1473-3099(23)00493-0. Epub 2023 Sep 28.
8
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.奥密克戎 BA.2 波期间香港住院的 COVID-19 患者无入院时吸氧需求的患者中早期莫努匹韦或奈玛特韦-利托那韦的真实世界疗效：一项回顾性队列研究。
Lancet Infect Dis. 2022 Dec;22(12):1681-1693. doi: 10.1016/S1473-3099(22)00507-2. Epub 2022 Aug 24.
9
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.奥密克戎变异株流行期间香港社区居住、活动的经实验室确诊的 2 型严重急性呼吸综合征冠状病毒 2 感染患者中莫努匹韦和奈玛特韦/利托那韦对比死亡率、住院率和住院结局的真实世界疗效：一项观察性研究。
Lancet. 2022 Oct 8;400(10359):1213-1222. doi: 10.1016/S0140-6736(22)01586-0.
10
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis.抗病毒药物治疗非重症 COVID-19：系统评价和网络荟萃分析。
CMAJ. 2022 Jul 25;194(28):E969-E980. doi: 10.1503/cmaj.220471.

本文引用的文献

1
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.严重急性呼吸综合征冠状病毒2的联合治疗可降低莫努匹拉韦诱导的致突变性并防止对奈玛特韦/利托那韦耐药突变的选择。
J Infect Dis. 2024 Dec 16;230(6):1380-1383. doi: 10.1093/infdis/jiae213.
2
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.SARS-CoV-2 病毒学反弹与奈玛特韦-利托那韦治疗：一项观察性研究。
Ann Intern Med. 2023 Dec;176(12):1577-1585. doi: 10.7326/M23-1756. Epub 2023 Nov 14.
3
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.联合使用莫努匹韦-奈玛特韦能提高对食蟹猴体内 SARS-CoV-2 的抑制效果。
JCI Insight. 2023 Feb 22;8(4):e166485. doi: 10.1172/jci.insight.166485.
4
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.SARS-CoV-2 对奈玛特韦产生耐药性的多种途径。
Nature. 2023 Jan;613(7944):558-564. doi: 10.1038/s41586-022-05514-2. Epub 2022 Nov 9.
5
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.